Preliminary results from the MITO 40 study presented at ESGO 2025 suggest Niraparib as a promising maintenance treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback